Non-malignant Hematology

LSC can help build landscape assessments, patient identification strategies, CoE activation, market access and reimbursement strategies for blood disorder therapies.

Case Studies

Mapped key decisions and drivers of adoption for a blockbuster hematology product, informing strategic planning at a large pharmaceutical company looking to expand to new indications

Analyzed a market entry strategy for a large, global pharmaceutical company to ensure it aligned with expected capacity and could be supported by its expected economic impact

Market and patient access scenario planning for a pipeline hemophilia asset

State Medicaid coverage assessment for a novel hemophilia drug

Characterized the KOL and CoE Landscape for a pediatric dysregulation syndrome to support pre-commercialization planning at a mid-sized pharmaceutical company